Please login to the form below
talimogene laherparepvec
This page shows the latest talimogene laherparepvec news and features for those working in and with pharma, biotech and healthcare.
Transgene slumps as viral cancer therapy fails phase 3 trial
It’s an approach that has already yielded one FDA- and EMA-approved product – Amgen’s Imlygic (talimogene laherparepvec) – which was launched in 2015 for melanoma but hasn’t made much
Latest news
-
Boehringer bolts on another immuno-oncology company
Oncolytic virus-based therapies are consistent with and complement that strategy.”. The first oncolytic virus therapy to reach western markets was Amgen’s Imlygic (talimogene laherparepvec or T-Vec) which was
-
Vyriad inks immunotherapy alliance with Merck/Pfizer
The first and so far only therapy of this type to reach the market is Amgen’s melanoma therapy Imlygic (talimogene laherparepvec or T-Vec, approved by the FDA in 2015,
-
J&J pays $140m upfront for cancer-busting virus firm BeneVir
Amgen’s Imlygic (talimogene laherparepvec) has been approved in Europe and the US since 2015 for use in melanoma that has recurred after surgery, but sales have been small.
-
Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal
This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic
-
NICE turns down CDF drug Adcetris in draft guidance
Imlygic (talimogene laherparepvec) was turned down by NICE in earlier guidance, with the agency arguing that it could not justify its use because of uncertainty about the therapy's effects on
Boehringer bolts on another immuno-oncology company
Vyriad inks immunotherapy alliance with Merck/Pfizer
J&J pays $140m upfront for cancer-busting virus firm BeneVir
NICE turns down CDF drug Adcetris in draft guidance
More from news
Approximately 4 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and kills cancer cells, and to date a handful of therapies – Amgen’s Imlygic (talimogene laherparepvec) in the US and
Cancer immunotherapy: What's on the horizon?
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Account Management
-
Competitive Salary Offered
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Account Manager
-
Competitive Salary
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Senior Medical Writer
-
Competitive Salary
-
Senior Account Executive
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
-
Medical Editor
-
Competitive Salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Publications Director
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Associate Account Director
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Merck & Co reveals plans for women’s health spinoff Organon
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- bluebird bio aiming to separate business units by year-end
- FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
- Single dose of COVID-19 vaccines ‘significantly’ reduces infections
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- Clark Health promotes Siân Hurst to managing director role
- ENGINE MHP+Mischief bolsters healthcare comms expertise with new senior hires
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Pfizer warns that IP waiver for COVID-19 vaccines may invite ‘copycat medicines’
- EMA introduces new measures to enable flexibility for non-COVID-19 procedures
- Pfizer asks UK's MHRA to approve its COVID-19 vaccine in adolescents
- New court filing alleges Sanofi destroyed emails relating to Zantac recall
- Merck & Co reveals plans for women’s health spinoff Organon
- Virtual agency The Difference Collective makes new hires to senior team
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- The impact of cancer on mental health during COVID-19
PMHub
Fishawack Health
Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
